apocell Home Contact Us

Illuminating biomarker detection – Leading the way in personalized medicine.

Darren Davis, Ph.D.
President and CEO

Darren Davis is a world recognized cancer researcher who has published 40 scientific articles and edited the book Antiangiogenic Cancer Therapy. Dr. Davis founded ApoCell in 2004 to commercialize biomarker technologies that monitors the effectiveness of cancer drugs by measuring biomarker expression patterns in tumor biopsy specimens. The proprietary method was developed to discover and validate methods to assess the effects of cancer drugs directed at specific molecular targets including antiangiogenic therapies. Dr. Davis received his doctorate from the University of Texas Health Science Center School of Biomedical Sciences and M.D. Anderson Cancer Center, Houston.

David K. Hasegawa, M.S.
Vice President, Product Development

David Hasegawa has over 30 years of experience in product development, including 15+ years of senior engineering management experience with firms focusing on medical device and diagnostic system development in accordance with FDA CFR 820 and ISO 13485. Positions held by Mr. Hasegawa include: Vice President, Product Development at BC Tech, a firm specializing in medical devices where he was responsible for all product development programs; Director, Device at Novo Nordisk, where he was responsible for building and managing device department to develop and manufacture an electro-mechanical pulmonary drug delivery device; and Director, Device Development at Aradigm where he was responsible for driving technical feasibility studies in support of development of pulmonary drug delivery devices. He received both his BS in Engineering Science (focus on bio-engineering) and his MS in Mechanical Engineering from the University of California, Berkeley. He is a licensed professional engineer through the California Board for Professional Engineers and Land Surveyors.

Asifa Haider, Ph.D.
Scientific Manager

Asifa Haider is a dedicated scientist with fifteen years of basic/translational research experience in oncology and immunology biomarker development. She is recognized for impact to these fields as demonstrated by numerous (~23) peer reviewed publications, awards, patent applications and as a principal investigator on clinical grant. She graduated from the Federal Institute of Technology (ETH-Zurich), Switzerland as a licensed pharmacist. Inspired by the interaction with patients and limitations of available treatments, she pursued translational research and received her doctorate in molecular pharmacology from New York Medical College. She studied the role of drugs targeting uncontrolled proliferation in response to deregulated inflammatory pathways. As a post-doctoral associate at Rockefeller University, she evaluated cutting edge technologies to study pharmacogenomics of predictive and prognostic biomarkers in patients’ blood-or tissue derived immune cells. She continued to work on biomarker development in the field of oncology as Principal Scientist at Novartis Pharmaceuticals, NJ.